Lyfebulb Connect Hosts Event in New York City With Orgenesis, With Focus on Working Toward a Practical Cure for Type 1 Diabetes

NEW YORK, NY -- (Marketwired) -- 12/07/15 -- Lyfebulb, an organization dedicated to improving the quality of life for people living with chronic disease, and Orgenesis Inc. (OTCQB: ORGS), will co-host the December 8 Lyfebulb Connect event from 6 to 8 p.m. at Le Colonial NYC 149 East 57th Street, New York City. The event offers an opportunity for guests to connect and learn about emerging therapies for Type 1 Diabetes and the progression toward a practical cure.

"This event will be an opportunity to learn first-hand about the diabetes research from Orgenesis, an emerging company dedicated to developing a practical cure for Type 1 Diabetes," Dr. Karin Hehenberger, CEO and Founder of Lyfebulb said. "We are thrilled to give our community and colleagues a glimpse of a new regenerative medicine therapy in development that attempts to use the body's own liver cells to help free patients from insulin dependence."

Speakers will include Dr. Karin Hehenberger, as well as a state of affairs in clinical diabetes by Stuart Weiss, MD, Clinical assistant Professor, Endocrinology, department of Medicine, NYU Langone Medical Center (not affiliated with the company) and Sarah Ferber, PhD Founder and CSO of Orgenesis. Scott Carmer, CEO Orgenesis North America, will conclude the evening's presentations with a summary of how the Orgenesis technology may provide a practical cure for patients living with Type 1 Diabetes.

The "cellular trans-differentiation" technology, being developed by Orgenesis involves a process reprogramming a particular adult cell type to then function as an adult cell of a different type. In this case liver cells are reprogrammed to function as pancreatic beta cells in that they can become glucose-responsive, insulin-producing cells.

Lyfebulb Connect hosts monthly events to connect individuals with chronic disease in a positive, interactive environment. Each event highlights a chronic illness and offers members a space to freely discuss their conditions. Lyfebulb Connect features guest speakers, patient representatives, new products, as well as many other useful ideas for anyone living with a chronic condition. To become a member and hear about upcoming events, visit

About Lyfebulb
Lyfebulb is a patient-centric organization whose mission is to improve the quality of life for people living with chronic disease NOW. The goal is to connect people, inspire them to change behavior and impact their lives. Through the monthly Lyfebulb Connect Events, the active online community, Lyfebulb functions as a bridge between patients and industry through working directly with companies in advisory roles. For more information, please visit

About Dr. Karin Hehenberger
Dr. Hehenberger is a health and wellness expert, with over 15 years of experience in the healthcare industry, ranging from executive positions with JNJ, JDRF, Eyetech, and most recently Coronado Biosciences, to partnership roles at private and public investments firms. Dr. Hehenberger trained as an MD and Ph.D. at the Karolinska Institute, Sweden, and did her post-doctoral fellowship at the Joslin Diabetes Center, Harvard Medical School. She is the founder and CEO of Lyfebulb, and also on the executive team at Immune Pharmaceuticals as Senior Vice President, Medical Affairs and Corporate Communications, responsible for the company's external communications and relationships with key opinion leaders, patient advocacy groups, media and investors.

About Orgenesis Inc.
Orgenesis is a cell therapy and regenerative medicine company that is committed to developing a cure for Type 1 Diabetes. In pursuit of this goal, the company has developed and patented a novel technology called "cellular trans-differentiation" that turns an insulin-dependent patient's own liver cells into functional insulin producing cells. Orgenesis has proven that, when exposed ex-vivo to certain pancreatic transcription factors and in specific sequence, human adult liver cells can be transformed into fully functional, beta cell-like insulin producing cells (IPCs). After ex-vivo expansion, the IPCs are re-infused via the portal vein of the diabetic patient. In pre-clinical models of Type 1 Diabetes (Non-Obese Diabetic mice), the re-introduced IPCs remain in the liver, effectively respond to glucose challenge and successfully maintain glycemic homeostasis. In the same NOD model, the implanted IPCs were not subject to auto-immune attack or cellular ablation. Orgenesis plans to initiate P1/2 trials in the next 12-18 months. Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. For more information, visit

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" which are not purely historical. Such forward-looking statements include, among other things, the expectations of management that our regeneration technology can be developed as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; that we can develop the technology to turn a small number of cells into a large number of cells; and that we will initiate Phase I and Phase II clinical trials in the near-term. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits Orgenesis will obtain from them. Actual results could differ from those projected in any forward-looking statements due to numerous factors, including, among others, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing; the ability to pass clinical trials so as to move on to the next phase; our technology may not as well as expected, our ability to retain key employees; our ability to finance development and operations; our ability to satisfy the rigorous regulatory requirements for new medical procedures; and competitors may develop better or cheaper alternatives to our products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should refer to the risk factors disclosure outlined in our periodic reports filed from time-to-time with the Securities and Exchange Commission.

Media Contact:
Tim Rush

Source: Orgenesis Inc.